Karl Nägler
Principal
Business and Management
Gimv
Belgium
Biography
Karl Nägler joined Gimv in 2011. Having started his professional career in 2002 at Atlas Venture in London and Munich, he later joined Ventech, a Paris-based venture capital firm focused on Europe and China. Karl has a successful track record in early and later stage Life Science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe, including U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (acquired by Horizon Pharma, HZNP:US), Egalet (EGLT:US), Funxional Therapeutics (acquired by Boehringer Ingelheim) and Themis. Since he joined Gimv, Karl has led investments into Prosonix (acquired by Circassia, CIR:LN), Covagen (acquired by Johnson & Johnson, JNJ:US) and Biom'up and has represented Gimv on the boards of those companies as well as on the board of Actogenix (acquired by Intrexon, XON:US). Previously, Karl had worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg (France) and holds a PhD in the area of molecular neurobiology from the Max-Delbrück-Center for Molecular Medicine (Berlin) and a Diploma in Biology from the Free University of Berlin.
Research Interest
Business and Management
